Treatment side effects: Case 1. Radiation recall phenomenon after administration of capecitabine

Journal of Clinical Oncology

Volumn 20, Issue 13, 2002, Pages 3029-3030

  Ortmann, Elisabeth ^a   Hohenberg, Gerda ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; PRODRUG; THYMIDINE PHOSPHORYLASE;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CASE REPORT; DRUG ACTIVATION; ERYTHEMA; FEMALE; HUMAN; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE;

EID: 0036644860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.13.3029     Document Type: Article

References (5)

1. Characterizing the phenomenon of radiation recall dermatitis
2. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
3. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models
4. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts
5. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts